Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRIS-PSC: Phase 2a randomized, double-blind, dose-ranging, placebo-controlled study of PLN-74809 in primary sclerosing cholangitis
2020-001428-33Phase 2Unknown
- Sponsor
- Pliant Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bexotegrast in Primary Sclerosing Cholangitis (PSC) (4 arms), sponsored by Pliant Therapeutics. Primary endpoint: Safety and tolerability (adverse events). Status: unknown.
02
Drugs
bexotegrast
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2020-001428-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001428-33.